DELCATH SYSTEMS, INC.

Delcath Systems, Inc. is an interventional oncology company that specializes in treatments for primary and metastatic liver cancers. The company operates through a single business segment and develops liver-directed therapies designed to administer chemotherapy directly to the liver while restricting systemic exposure. Its primary commercial offerings include the HEPZATO KIT, an FDA-approved drug and device combination, and CHEMOSAT, a stand-alone hepatic delivery medical device marketed in Europe. Delcath provides these systems primarily to specialized cancer centers, hospital radiology departments, and treating oncologists caring for adult cancer patients.

The company conducts commercial and clinical activities across the United States and Europe. In the United States, Delcath has twenty-five active cancer center sites and thirty-two facilities accepting patient referrals. In Europe, its medical device is available in twenty-two cancer centers and has been administered in over two thousand commercial procedures. The company maintains its corporate headquarters in Queensbury, New York.

Summary of the business section of Delcath Systems's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of February 13, 2026, including our management team, we had approximately 156 full time employees, of which 141 are located in the United States and 15 are located in Europe.”